Reunion Neuroscience On The Brink Of Going Private With Final Court Approval
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ:REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution a
Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ:REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates. Here's a breakdown of the report
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Specialty biotech company PharmaTher Holdings Ltd. (OTCQB:PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic keta
Can Field Trip Health & Wellness Re-Emerge From Creditor Protection? What The CCAA Data Shows
Potentially, a significant business casualty has befallen the psychedelic sector. Early industry leader, Field Trip Health & Wellness (OTC:FTHWF), has announced that it has obtained an Order for credi
Express News | Field Trip Health & Wellness Ltd. Brief: Says Has Obtained CCAA Protection
In-Clinic Ketamine Businesses Are Shutting Down All Across The US, A Rising Trend?
Closely following the announcement of what's to become of the new regulations for telehealth, including ketamine therapy, several of in-clinic treatment centers have announced they are closing their o
Field Trip Health & Wellness to Close Clinics in 5 Locations
TORONTO, March 15, 2023 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSX-V: FTHW) ("Field Trip" or the "Company") today announced that, in an effort to reduce expenditures and preserve cap
Field Trip H&W Closes Q3 2023 On Material Uncertainty, Need To Lower Costs & Adapt To New Regulations
Ketamine therapy provider Field Trip Health & Wellness Ltd. (OTCQB:FTHWF) shared its Q3 2023 results for three and nine months ended Dec. 31, 2022 and some of the period's highlights. Financials: As
Field Trip Health & Wellness Provides Business Update and Reports Fiscal Third Quarter 2023 Results
TORONTO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (OTCQB: FTHWF) (the "Company" or "Field Trip"), a global leader in the delivery of psychedelic therapies, pr
Field Trip Health & Wellness Ltd. to Release Fiscal 2023 Third Quarter Financial Results on Tuesday, February 28, 2023
TORONTO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (OTCQB: FTHWF) (the "Company" or "Field Trip"), a global leader in the delivery of psychedelic therapies, an
'Sea Change': Irwin Naturals, Numinus And Field Trip Discuss Psychedelics At Cantor Webinar
Cantor Fitzgerald's Pablo Zuanic hosted a virtual panel discussion about the psychedelics industry with three ketamine therapy providers: Irwin Naturals (OTC:IWINF)' CEO Klee Irwin, Field Trip H&W (OT
Express News | Field Trip Health & Wellness Ltd. Brief: Trading on the OTCQB Effective February 2, 2023, Under the Symbol "FTHWF"
Field Trip Health & Wellness Announces Posting on the OTC Market
Trading on the OTCQB Effective February 2, 2023, under the Symbol "FTHWF"TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or "Field Trip"), gl
Irwin Naturals, Numinus, Field Trip: Sector Analyst Compares Footprints, Cash, Organic Growth
The Analyst Analyst Pablo Zuanic from Cantor Fitzgerald kept an Overweight rating for Irwin Naturals (CSE:IWIN) (OTC:IWINF) but lowered its 12-month price target to US$6.00 (C$8.05) from US$6.20 "on a
Field Trip Health & Wellness Ltd. Announces Updated Time for Fiscal Second Quarter 2023 Financial Results and Conference Call
TORONTO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSXV:FTHW) (the "Company" of "Field Trip"), a global leader in the delivery of psychedelic therapies, announced today that it
Field Trip Health & Wellness Ltd. Strengthens Leadership Team With Two Executive Appointments, Schedules Fiscal Second Quarter 2023 Conference Call
These Are The Top Companies And Most Influential People In The Psychedelics Space: Meet The Winners Of The Microdose Awards
Which are the top companies and who are the most influential people in the psychedelics space? According to Microdose Psychedelic Insights, host of the Microdose Awards, these are the ones to watch. T
Field Trip Health & Wellness Reports Q1 Results
Field Trip Health & Wellness press release (OTCPK:FTHWF): Q1 Revenue of C$1.82M (+109.2% Y/Y). Net loss for the clinics was C$8.2M
Field Trip Health & Wellness Ltd. Reports Fiscal First Quarter 2023 Financial and Operating Results
Completed corporate reorganization on August 11, 2022 separating the drug development ("Reunion Neuroscience Inc." or "Reunion") and healthcare and wellness ("Field Trip Health & Wellness" or "Fie
Field Trip Health & Wellness Ltd. Schedules Fiscal First Quarter 2023 Conference Call for Tuesday, August 30, 2022, at 8:30 A.M. ET
TORONTO, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSXV:FTHW) (the "Company" or "Field Trip"), a global leader in psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first qua
No Data